BioAtla, Inc. (BCAB) Social Stream
BIOATLA INC (BCAB) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering BCAB.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-18 | 4 | $75 | $64 | $70.5 | $2.45 | 2777.55% |
| 2022-01-02 | 4 | $75 | $58 | $69 | $2.45 | 2716.33% |
| 2022-01-12 | 3 | $75 | $58 | $69 | $2.45 | 2716.33% |
| 2022-01-17 | 3 | $75 | $58 | $67.25 | $2.45 | 2644.9% |
| 2022-02-04 | 3 | $68 | $36 | $57.5 | $2.45 | 2246.94% |
| 2022-03-01 | 3 | $68 | $36 | $53.5 | $2.45 | 2083.67% |
| 2022-03-11 | 3 | $68 | $31 | $46.75 | $2.45 | 1808.16% |
| 2022-05-05 | 4 | $68 | $25 | $42.4 | $2.45 | 1630.61% |
| 2022-05-06 | 4 | $68 | $21 | $36.2 | $2.45 | 1377.55% |
| 2022-07-22 | 4 | $68 | $21 | $37.5 | $2.45 | 1430.61% |
| 2022-08-10 | 4 | $68 | $20 | $34.2 | $2.45 | 1295.92% |
| 2022-09-15 | 5 | $68 | $17 | $30.833 | $2.45 | 1158.49% |
| 2022-11-04 | 5 | $36 | $17 | $23.6 | $2.45 | 863.27% |
| 2023-01-05 | 6 | $36 | $17 | $23.833 | $2.45 | 872.78% |
| 2023-03-24 | 5 | $25 | $17 | $20.8 | $2.45 | 748.98% |
| 2023-03-27 | 6 | $25 | $12 | $18.4 | $2.45 | 651.02% |
| 2023-03-28 | 6 | $25 | $12 | $17.5 | $2.45 | 614.29% |
| 2023-08-02 | 6 | $25 | $12 | $16.333 | $2.45 | 566.65% |
| 2023-09-25 | 6 | $25 | $12 | $15.833 | $2.45 | 546.24% |
| 2023-11-08 | 6 | $25 | $10 | $14.8 | $2.45 | 504.08% |
The Trend in the Analyst Price Target
BCAB's average price target has moved down $61.58 over the prior 28 months.
BCAB reports an average of 493.65% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-24 | 5 | 25 | 17 | 20.800 | 2.36 | 781.36% |
| 2023-04-03 | 6 | 25 | 12 | 16.833 | 2.83 | 494.81% |
| 2023-08-02 | 6 | 25 | 12 | 16.666 | 2.98 | 459.26% |
| 2023-08-02 | 6 | 25 | 12 | 16.333 | 2.98 | 448.09% |
| 2023-09-25 | 6 | 25 | 12 | 15.833 | 1.72 | 820.52% |
BCAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
BCAB's average broker recommendation rating improved by 0 over the prior 31 weeks.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, BIOATLA INC's upside potential (average analyst target price relative to current price) is greater than 2809.95% of them.
- In terms of how BIOATLA INC fares relative to all US stocks, note that its number of analysts covering the stock is higher than 527.43% of that group.
- In the context of stocks in the mid market cap category, BIOATLA INC's variance in analysts' estimates is lower than -1913.98% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, BIOATLA INC's average analyst price target is greater than 1247.6% of them.
In the Pharmaceutical Products industry, TIL, RXRX, and EXAI are the three stocks most similar to BIOATLA INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for BCAB? Use POWR Ratings for clearer insight into price direction.